03445nam2-22005171i-450-99000018617040332120120927144438.0000018617FED01000018617(Aleph)000018617FED0100001861720020821g19119999km-y0itay50------bamulDEy-------001yyOpera mathematicaLeonhard EulerLeipzigB.G. Teubner1911-v.30 cm1.: Vollständige Anleitung zur Algebra / Leonhard Euler; mit den Zusätzen von Joseph Louis Lagrange ; herausgegeben von Heinrich Weber2.-3.: Leonhardi Euleri Commentationes arithmeticae. 1-2 / edidit Ferdinand Rudio6.: Leonhardi Euleri Commentationes algebraicae ad theoriam aequationum pertinentes / ediderunt Ferdinand Rudio, Adolf Krazer, Paul Stackel7.: Leonhardi Euleri Commentationes algebraicae ad theoriam combinationum et probabilitatum pertinentes / edidit Louis Gustave Du Pasquier8.: Leonhardi Euleri Introductio in analysin infinitorum. 1 / ediderunt Adolf Krazer et Ferdinand Rudio10.: Leonhardi Euleri Institutiones calculi differentialis / edidit Gerhard Kowalewski11.: Leonhardi Euleri Institutiones calculi integralis. 1 / ediderunt Friedrich Engel et Ludwig Schlesinger12.: Leonhardi Euleri Institutiones calculi integralis. 2 : adiectae sunt Laurentii Mascheronii adnotationes ad calculum integralem Euleri / ediderunt Friedrich Engel et Ludwig Schlesinger13.: Leonhardi Euleri Institutiones calculi integralis. 3 / ediderunt Friedrich Engel et Ludwig Schlesinger14.: Leonhardi Euleri Commentationes analyticae ad theoriam serierum infinitarum pertinentes. 1 / ediderunt Carl Boehm et Georg Faber15.: Leonhardi Euleri Commentationes analyticae ad theoriam serierum infinitarum pertinentes. 2 / edidit Georg Faber17.: Leonhardi Euleri Commentationes analyticae ad theoriam integralium pertinentes. 1 / edidit August Gutzmer18.: Leonhardi Euleri Commentationes analyticae ad theoriam integralium pertinentes. 2 / ediderunt August Gutzmer et Alexander Liapounoff19.: Leonhardi Euleri Commentationes analyticae ad theoriam integralium pertinentes. 3 / ediderunt Alexander Liapounoff, Adolf Krazer, Georg Faber20.-21.: Leonhardi Euleri Commentationes analyticae ad theoriam integralium ellipticorum pertinentes. 1-2 / edidit Adolf Krazer24.: Methodus inveniendi lineas curvas... /edidit Constantin Carathéodory0010000160462001Leonhardi Euleri opera omnia500Euler,Leonhard<1707-1783>8600ITUNINARICAUNIMARCBK99000018617040332113 N 53 01351FINBC13 N 53 024192FINBC13 N 53 034193FINBC13 N 53 044312FINBC13 N 53 055450FINBC13 N 53 064624FINBC13 N 53 071018FINBC13 N 53 081089FINBC13 N 53 092073FINBC13 N 53 104195FINBC13 N 53 116231FINBC13 N 53 126936FINBC13 N 53 134191FINBC13 N 53 144194FINBC13 N 53 1517231FINBC13 N 53 16865FINBCTECN C 55818972FARBCFINBCFARBCOpera mathematica122414UNINA05475nam 2200661 450 991081724960332120200520144314.03-527-66523-43-527-66521-83-527-66524-2(CKB)3710000000202706(EBL)1744759(SSID)ssj0001353448(PQKBManifestationID)12507327(PQKBTitleCode)TC0001353448(PQKBWorkID)11315520(PQKB)10562333(MiAaPQ)EBC1744759(Au-PeEL)EBL1744759(CaPaEBR)ebr10901883(OCoLC)884646529(PPN)190251387(EXLCZ)99371000000020270620140814h20142014 uy 0engur|n|---|||||txtccrStructure-based design of drugs and other bioactive molecules tools and strategies /Arun K. Ghosh and Sandra GemmaWeinheim, Germany :Wiley-VCH,2014.©20141 online resource (476 p.)Description based upon print version of record.3-527-33365-7 Includes bibliographical references at the end of each chapters and index.Structure-based Design of Drugs and Other Bioactive Molecules: Tools and Strategies; Contents; Preface; 1 From Traditional Medicine to Modern Drugs: Historical Perspective of Structure-Based Drug Design; 1.1 Introduction; 1.2 Drug Discovery During 1928-1980; 1.3 The Beginning of Structure-Based Drug Design; 1.4 Conclusions; References; Part One: Concepts, Tools, Ligands, and Scaffolds for Structure-Based Design of Inhibitors; 2 Design of Inhibitors of Aspartic Acid Proteases; 2.1 Introduction; 2.2 Design of Peptidomimetic Inhibitors of Aspartic Acid Proteases2.3 Design of Statine-Based Inhibitors2.4 Design of Hydroxyethylene Isostere-Based Inhibitors; 2.5 Design of Inhibitors with Hydroxyethylamine Isosteres; 2.5.1 Synthesis of Optically Active α-Aminoalkyl Epoxide; 2.6 Design of (Hydroxyethyl)urea-Based Inhibitors; 2.7 (Hydroxyethyl)sulfonamide-Based Inhibitors; 2.8 Design of Heterocyclic/Nonpeptidomimetic Aspartic Acid Protease Inhibitors; 2.8.1 Hydroxycoumarin- and Hydroxypyrone-Based Inhibitors; 2.8.2 Design of Substituted Piperidine-Based Inhibitors; 2.8.3 Design of Diaminopyrimidine-Based Inhibitors2.8.4 Design of Acyl Guanidine-Based Inhibitors2.8.5 Design of Aminopyridine-Based Inhibitors; 2.8.6 Design of Aminoimidazole- and Aminohydantoin-Based Inhibitors; 2.9 Conclusions; References; 3 Design of Serine Protease Inhibitors; 3.1 Introduction; 3.2 Catalytic Mechanism of Serine Protease; 3.3 Types of Serine Protease Inhibitors; 3.4 Halomethyl Ketone-Based Inhibitors; 3.5 Diphenyl Phosphonate-Based Inhibitors; 3.6 Trifluoromethyl Ketone Based Inhibitors; 3.6.1 Synthesis of Trifluoromethyl Ketones; 3.7 Peptidyl Boronic Acid-Based Inhibitors3.7.1 Synthesis of α-Aminoalkyl Boronic Acid Derivatives3.8 Peptidyl α-Ketoamide- and α-Ketoheterocycle-Based Inhibitors; 3.8.1 Synthesis of α-Ketoamide and α-Ketoheterocyclic Templates; 3.9 Design of Serine Protease Inhibitors Based Upon Heterocycles; 3.9.1 Isocoumarin-Derived Irreversible Inhibitors; 3.9.2 β-Lactam-Derived Irreversible Inhibitors; 3.10 Reversible/Noncovalent Inhibitors; 3.11 Conclusions; References; 4 Design of Proteasome Inhibitors; 4.1 Introduction; 4.2 Catalytic Mechanism of 20S Proteasome; 4.3 Proteasome Inhibitors; 4.3.1 Development of Boronate Proteasome Inhibitors4.3.2 Development of β-Lactone Natural Product-Based Proteasome Inhibitors4.3.3 Development of Epoxy Ketone-Derived Inhibitors; 4.3.4 Noncovalent Proteasome Inhibitors; 4.4 Synthesis of β-Lactone Scaffold; 4.5 Synthesis of Epoxy Ketone Scaffold; 4.6 Conclusions; References; 5 Design of Cysteine Protease Inhibitors; 5.1 Introduction; 5.2 Development of Cysteine Protease Inhibitors with Michael Acceptors; 5.3 Design of Noncovalent Cysteine Protease Inhibitors; 5.4 Conclusions; References; 6 Design of Metalloprotease Inhibitors; 6.1 Introduction; 6.2 Design of Matrix Metalloprotease Inhibitors6.3 Design of Inhibitors of Tumor Necrosis Factor-α-Converting EnzymesIn contrast to previous texts focusing on either computational, structural or synthetic methods, this one-of-a-kind guide integrates all three skill sets for a complete picture of contemporary structure-based design.As a result, this practical book demonstrates how to develop a high-affinity ligand with drug-like properties for any given drug target for which a high-resolution structure exists. The authors, both of whom have successfully designed drug-like molecules that were later developed into marketed drugs, use numerous examples of recently developed drugs to present best practice inDrug developmentData processingBioactive compoundsAnalysisBiopolymersIdentificationDrug developmentData processing.Bioactive compoundsAnalysis.Biopolymers615.190285Ghosh Arun K.1636192MiAaPQMiAaPQMiAaPQBOOK9910817249603321Structure-based design of drugs and other bioactive molecules3977355UNINA